Literature DB >> 19803714

Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women.

Ather Mansoor1, Keri Althoff, Stephen Gange, Kathryn Anastos, Jack Dehovitz, Howard Minkoff, Robert Kaplan, Susan Holman, Jason M Lazar.   

Abstract

HIV infection is associated with left ventricular (LV) dysfunction and accelerated atherosclerosis. These conditions result in elevation of plasma natriuretic peptide (NP) levels. The present study compares N-terminal-pro-BNP (NT-pro-BNP) levels in HIV-infected and -uninfected women and identifies factors influencing NT-pro-BNP levels in HIV-infected women. A total of 454 HIV-infected and 200 HIV-uninfected participants from the Women's Interagency HIV Study (WIHS) had NT-pro-BNP determination. Elevated NT-pro-BNP level was defined using previously determined age stratified cut-off values of >164 ng/liter (age <60 years) and >225 (age > or = 60 years). HIV-infected women were older (41.6 +/- 8.9 vs. 38.9 +/- 10.5 years, p < 0.01) and were more likely to have anemia, hepatitis C virus (HCV) antibodies, and kidney dysfunction than HIV-uninfected women. HIV-infected women had significantly higher NT-pro-BNP levels (142.4 +/- 524.8 vs. 73.6 +/- 115.1 ng/liter, p = 0.01) and a higher prevalence of elevated NT-pro-BNP (12.1% vs. 7.5%; p = 0.08). In univariate analyses, elevated NT-pro-BNP was significantly associated with age, systolic BP, hypertension, anemia, triglyceride levels, kidney disease, and HCV seropositivity, but not HIV infection. In multivariate analysis, elevated NT-pro-BNP levels were significantly associated with anemia and kidney function, and had a borderline association with the presence of HCV antibodies. Among HIV-infected women, NT-pro-BNP levels were not independently associated with measures of severity of infection or with HAART use. Although HIV-infected women have higher NT-pro-BNP levels than HIV-uninfected women, the differences are due to non-HIV factors such as anemia, kidney disease, and HCV coinfection. These findings suggest that natriuretic peptide levels are a global marker of comorbidity in the setting of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19803714      PMCID: PMC2791362          DOI: 10.1089/aid.2009.0038

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  Prevalence of cardiac abnormalities in human immunodeficiency virus infection.

Authors:  W S Levy; G L Simon; J C Rios; A M Ross
Journal:  Am J Cardiol       Date:  1989-01-01       Impact factor: 2.778

3.  The clinical course of idiopathic dilated cardiomyopathy. A population-based study.

Authors:  D D Sugrue; R J Rodeheffer; M B Codd; D J Ballard; V Fuster; B J Gersh
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

4.  Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure.

Authors:  M G Buckley; D Sethi; N D Markandu; G A Sagnella; D R Singer; G A MacGregor
Journal:  Clin Sci (Lond)       Date:  1992-10       Impact factor: 6.124

5.  Myocardial dysfunction in patients infected with HIV: prevalence and risk factors.

Authors:  A J Jacob; G R Sutherland; A G Bird; R P Brettle; C A Ludlam; A McMillan; N A Boon
Journal:  Br Heart J       Date:  1992-12

6.  Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension.

Authors:  Paavo Uusimaa; Heikki Tokola; Antti Ylitalo; Olli Vuolteenaho; Heikki Ruskoaho; Juha Risteli; Markku Linnaluoto; Keijo Peuhkurinen
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

7.  Heart involvement in AIDS: a prospective study during various stages of the disease.

Authors:  S De Castro; G Migliau; A Silvestri; G D'Amati; P Giannantoni; D Cartoni; A Kol; V Vullo; A Cirelli
Journal:  Eur Heart J       Date:  1992-11       Impact factor: 29.983

8.  Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography.

Authors:  Anne-Mette Lebech; Jan Gerstoft; Birger Hesse; Claus Leth Petersen; Andreas Kjaer
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

9.  Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Authors:  Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

10.  Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Authors:  Jasmine Grewal; Robert S McKelvie; Hans Persson; Peter Tait; Jonas Carlsson; Karl Swedberg; Jan Ostergren; Eva Lonn
Journal:  Am J Cardiol       Date:  2008-07-09       Impact factor: 2.778

View more
  16 in total

1.  Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women.

Authors:  Howard A Crystal; Jeremy Weedon; Susan Holman; Jennifer Manly; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Wendy J Mack; Elizabeth Golub; Jason Lazar; Ann Ho; Mary Jeanne Kreek; Robert C Kaplan
Journal:  J Neurovirol       Date:  2011-10-18       Impact factor: 2.643

2.  Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Women's Interagency HIV Study.

Authors:  Deborah R Gustafson; Michelle M Mielke; Phyllis C Tien; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Leigh Pearce; Elizabeth T Golub; Howard Minkoff; Howard A Crystal
Journal:  J Neurovirol       Date:  2013-12-12       Impact factor: 2.643

3.  Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.

Authors:  Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

4.  Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure.

Authors:  Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

5.  Leptin, Adiponectin and Cognition in Middle-aged HIV-infected and Uninfected Women. The Brooklyn Women's Interagency HIV Study.

Authors:  Deborah R Gustafson; Michelle M Mielke; Sheila A Keating; Susan Holman; Howard Minkoff; Howard A Crystal
Journal:  J Gerontol Geriatr Res       Date:  2015-09-23

6.  N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.

Authors:  Daniel A Duprez; Jacqueline Neuhaus; Russell Tracy; Lewis H Kuller; Steven G Deeks; Chloe Orkin; Albrecht Stoehr; Ian J Woolley; James D Neaton
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

7.  HIV-positive youth who are perinatally infected have impaired endothelial function.

Authors:  Sahera Dirajlal-Fargo; Abdus Sattar; Manjusha Kulkarni; Emily Bowman; Nicholas Funderburg; Grace A McComsey
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.632

8.  Monocyte activation and gut barrier dysfunction in South African youth on antiretroviral therapy and their associations with endothelial dysfunction.

Authors:  Sahera Dirajlal-Fargo; Jiao Yu; Zainab Albar; Abdus Sattar; Sana Mahtab; Jennifer Jao; Landon Myer; Heather J Zar; Grace A McComsey
Journal:  AIDS       Date:  2020-09-01       Impact factor: 4.632

9.  Factors related to NT-proBNP levels in HIV patients aged over 40 years.

Authors:  Julián Olalla; Elena Crespo; Javier De la Torre; Marco Sempere; Alfonso Del Arco; José Luis Prada; Rocío Malvarez; Javier Pérez; Javier García-Alegría
Journal:  AIDS Res Ther       Date:  2015-05-10       Impact factor: 2.250

10.  N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR).

Authors:  Hoda Mirjafari; Paul Welsh; Suzanne M M Verstappen; Paddy Wilson; Tarnya Marshall; Helena Edlin; Diane Bunn; Jacqueline Chipping; Mark Lunt; Deborah P M Symmons; Naveed Sattar; Ian N Bruce
Journal:  Ann Rheum Dis       Date:  2013-03-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.